Loading...
•
Mar 31, 2021
Collegium Q1 2021 Earnings Report
Collegium reported record quarterly revenue and net income in the first quarter of 2021.
Key Takeaways
Collegium Pharmaceutical, Inc. reported record quarterly net revenue of $87.7 million and net income of $15.7 million for the first quarter ended March 31, 2021. The company experienced growth in Xtampza ER and Nucynta franchise revenues, and raised its Nucynta franchise and adjusted EBITDA 2021 guidance range.
Record quarterly net revenue achieved, driven by Xtampza ER and Nucynta franchise.
Xtampza ER market share grew to 30.6% in March 2021.
Colleen Tupper appointed as the Company’s next CFO, effective May 24, 2021.
Nucynta franchise and Adjusted EBITDA 2021 guidance range raised.
Revenue by Segment
Forward Guidance
The Company updates its full-year 2021 financial guidance for Nucynta Franchise Revenues and Adjusted EBITDA.
Positive Outlook
- Xtampza ER Revenues guidance unchanged at $155.0 to $165.0 million.
- Nucynta Franchise Revenues guidance raised from $175.0 to $185.0 million to $185.0 to $195.0 million.
- Total Operating Expenses guidance unchanged at $125.0 to $135.0 million.
- Adjusted EBITDA guidance raised from $160.0 to $170.0 million to $170.0 to $180.0 million.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...